Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation

Leukemia volume 20, pages 187–192 (2006)Cite this article

Abstract

A multicentric phase 2 study was conducted to determine the efficiency and the tolerance of imatinib mesylate in children with chronic myelogenous leukemia (CML) in advanced phase of the disease, in relapse after stem cell transplantation, or in case of failure to an interferon α-based regimen. In all, 30 children from eight European countries were enrolled. In 18 children assessable for hematologic response, imatinib mesylate induced complete hematologic response in eight (80%) of the 10 patients included in chronic phase and in six (75%) of eight enrolled in advanced phase of the disease with acceptable toxicity. In 27 patients assessable for cytogenetic response, imatinib mesylate induced disappearance of Philadelphia chromosome-positive bone marrow cells in 12 (60%) of 20 children included in chronic phase and in two (29%) of seven included in advanced phase. A reduction of the bcr-abl/abl ratio to less than 10−4 was achieved in 11 (50%) of the children included in chronic phase. Estimated 12-month overall survival rate was 95% (95% CI, 87–100%) for the patients included in chronic phase and 75% (95%CI, 45–100%) for those enrolled in advanced phase. Imatinib mesylate is well tolerated and molecular remission can be achieved in children with CML.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Ries LAG, Smith MA, Gurney JG . Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995. SEER Pediatric Monograph.

  2. Millot F, Esperou H, Bordigoni P, Dalle JH, Michallet M, Michel G et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Société Française de Greffe de Moelle et de Thérapie cellulaire. Bone Marrow Transplant 2003; 32: 993–999.

    Article  CAS  Google Scholar 

  3. Cwynarski K, Roberts IAG, Iacobelli S, Van Biezen A, Brand R, Devergie A et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood 2003; 102: 1224–1231.

    Article  CAS  Google Scholar 

  4. Munoz A, Bureo E, Ortega JJ, Richard C, Olive T, Madonaldo MS et al. Treatment of Ph1-positive chronic myelogenous leukemia in children: comparison between allogeneic bone marrow transplantation and conventional therapy. Haematologica 1998; 83: 981–984.

    CAS  PubMed  Google Scholar 

  5. Gamis AS, Haake R, McGlave P, Ramsey NK . Unrelated-donor bone marrow transplantation for Philadelphia chromosome-positive chronic myelogenous leukemia in children. J Clin Oncol 1993; 111: 834–838.

    Article  Google Scholar 

  6. Klingebiel T, Creutzig U, Dopfer R, Ehninger G, Schmidt H, Ritter J et al. Bone marrow transplantation in comparison with conventional therapy in children with adult type chronic myelogenous leukemia. Bone Marrow Transplant 1990; 5: 317–320.

    CAS  PubMed  Google Scholar 

  7. Millot F, Brice P, Philippe N, Thyss A, Demeoq F, Wetterwald M et al. Alpha-interferon in combination with cytarabine in children with Philadelphia-positive chronic myeloid leukemia. J Pediat Hematol Oncol 2002; 24: 18–22.

    Article  Google Scholar 

  8. Dow LW, Raimondi SC, Culbert SJ, Ochs J, Kennedy W, Pinkel DP . Response to alpha-interferon in children with Philadelphia chromosome-positive chronic myelocytic leukemia. Cancer 1991; 68: 1678–1684.

    Article  CAS  Google Scholar 

  9. Sawyers CL, Hochhaus A, Feldman E, Goldman0 JM, Miller CB, Ottmann OG et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530–3539.

    Article  CAS  Google Scholar 

  10. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia : results of a phase 2 study. Blood 2002; 99: 1928–1937.

    Article  CAS  Google Scholar 

  11. Champagne MA, Capdeville R, Krailo M, Qu W, Peng B, Rosamilia M et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia : results from a Children's Oncology Group phase 1 study. Blood 2004; 104: 2655–2660.

    Article  CAS  Google Scholar 

  12. Kantajian HM, Talpaz M, Cortes J, O'Brien S, Faderl S, Thomas D et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate in chronic-phase chronic mylogenous leukemia. Clin Cancer Res 2003; 9: 160–166.

    Google Scholar 

  13. Kolb EA, Pan Q, Ladanyi M, Steinherz PG . Imatinib mesylate in Philadelphia chromosome-positive leukemia in childhood. Cancer 2003; 98: 2643–2650.

    Article  CAS  Google Scholar 

  14. Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase 1 trial with chronic myeloid leukemia patients. J Clin Oncol 2004; 22: 935–942.

    Article  CAS  Google Scholar 

  15. Kantarjian HM, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukaemia. N Engl J Med 2002; 346: 645–652.

    Article  CAS  Google Scholar 

  16. Olavarria E, Ottmann OG, Deininger M, Clark RE, Bandini G, Byrne J et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2003; 17: 1707–1712.

    Article  CAS  Google Scholar 

  17. Rosti G, Martinelli G, Bassi S, Amabile M, Trabacchi E, Giannini B et al. Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. Blood 2004; 103: 2284–2290.

    Article  CAS  Google Scholar 

  18. Hughes TP, Kaeda J, Brandford S, Rudzki Z, Hochhaus A, Hensley ML et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423–1432.

    Article  CAS  Google Scholar 

  19. Kantarjian HM, O'Brien S, Cortes JE, Giralt SA, Rios MB, Shan J et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukaemia. Blood 2002; 100: 1590–1595.

    CAS  Google Scholar 

  20. Thornley I, Parentesis JP, Davies SM, Smith FO, Champagne M, Lipton JM . Treating children with chronic myeloid leukemia in the imatinib era: a therapeutic dilemma? Med Pediatr Oncol 2003; 41: 115–117.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, CHU la Milétrie, Poitiers, France

    F Millot, J Guilhot & F Guilhot

  2. Department of Pediatrics, Jeanne de Flandre Hospital, Lille, France

    B Nelken

  3. Department of Pediatrics, Saint Louis Hospital, Paris, France

    T Leblanc

  4. Department of Pediatric Oncology, Dutch Childhood Oncology Group, Den Hague, The Netherlands

    E S De Bont

  5. Department of Pediatrics, University Hospital, Lund, Sweden

    A N Békassy

  6. Department of Pediatric Oncology, Saint Anna Childrens Hospital, Vienna, Austria

    H Gadner

  7. Department of Pediatrics, University Hospital, Bratislava, Slovakia

    S Sufliarska

  8. Department of Pediatrics, University Hospital Motol, Prague, Czech Republic

    J Stary

  9. Novartis Pharma, Nurnberg, Germany

    H Gschaidmeier

  10. Department of Pediatric Hematology, University Childrens Hospital, Dresden, Germany

    M Suttorp

Authors
  1. F Millot
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Guilhot
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B Nelken
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T Leblanc
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E S De Bont
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A N Békassy
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H Gadner
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S Sufliarska
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J Stary
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. H Gschaidmeier
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. F Guilhot
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M Suttorp
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F Millot.

Additional information

Preliminary data were presented at the 45th annual meeting of the American Society of Hematology, San Diego, CA, December 6–9, 2003.

Appendix A

Appendix A

In addition to the authors, the following investigators participated in this trial: Claire Berger, Saint Etienne, France; Françoise Mazingue, Lille, France; Guy Leverger, Paris, France; Frédéric Bernard, Montpellier, France; Dominique Plantaz, Grenoble, France; Yves Bertrand, Lyon, France; Virginie Gandemer, Rennes, France.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Millot, F., Guilhot, J., Nelken, B. et al. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia 20, 187–192 (2006). https://doi.org/10.1038/sj.leu.2404051

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404051

Keywords

This article is cited by

Search

Advanced search

Quick links